View all the latest information in
, arranged by trials and clinical studies. Listed below are recently added trial updates.
New working definition of ruxolitinib-refractory acute GvHD
Mohamad Mohty, chair of the GvHD Hub Steering Committee, and colleagues published an article in Blood to define the patient population that...
REACH2: What patients with steroid-refractory acute GvHD respond best to ruxolitinib?
An interview from the 25th Congress of the EHA with Robert Zeiser, Medical Center – University of Freiburg,...
Remestemcel-L receives backing from the ODAC for the treatment of children with acute GvHD
On August 13, 2020, the Oncologic Drugs Advisory Committee of the U.S. Food and Drug administration deemed...
Treatment of SR-GvHD and subsequent trial updates at EHA 2020
This year at EHA2020, we will be providing coverage of the oral presentations that provide updates on the trials focusing on novel...
Ruxolitinib shows improved overall response rate for patients with chronic GvHD
The Reach3 trial compared ruxolitinib with standard cGVHD therapies, and topline results show that the ruxolitinib...
BMT Tandem Meetings | Study design of the REACH-3 trial using ruxolitinib in steroid refractory GvHD
The REACH-3 trial will review safety and efficacy of ruxolitinib in this population of pediatric...
EHA 2020 | Phase III GRAVITAS-301 trial results on itacitinib plus corticosteroids for aGvHD
The results from the phase III GRAVITAS-301 trial that investigated the efficacy of the Janus kinase 1...
The phase III GRAVITAS-301 study did not meet its primary endpoint of improving overall response rate (ORR)
The randomized, double-blind, placebo-controlled pivotal phase III study, GRAVITAS-301...
BMT CTN 1101
BMT CTN 1203
BMT CTN 1501